Market Size – USD 2132.5 Million in 2019, Market Growth – CAGR of 7.4%, Market Trends– growing prevalence of chronic asthma, potential investment opportunities and technological advancements is expected to fuel the market in the forecast period
The global Chronic Rhinosinusitis Market was valued at USD 2132.5 million in 2019 and is expected to reach USD 3508.0 million by 2027, at a CAGR of 7.4%, According to the current analysis of Emergen Research. Development and manufacture of proficient sinusitis drugs are likely to be highly demanded for efficient treatment of chronic rhinosinusitis as, pollutants, fungal infections and allergies immensely contribute to the rising incidence of rhinosinusitis. Moreover, growing prevalence of growing prevalence of chronic asthma, inflammation of mucosal linings of the nasal passage, and cases of paranasal sinuses are expected to fuel the growth prospects of chronic rhinosinusitis market in the forecast period.
Roughly more than 15 million people suffer from chronic symptoms of rhinosinusitis in the United States, that is, prevalence of chronic rhinosinusitis ranges from 1% to 5% of the total US population. Chronic rhinosinusitis is primarily characterized by nasel blockage, inflammation of the sinus and nasel linings, facial pain along with rhinorrhea and loss of sense of smell. Effective treatment includes improvement in sinus outflow, enhancement of mucociliary clearance and elimination of inflammation and local infection among other associated treatments.
Key players in the market include AstraZeneca, Bayer AG, Ivax Pharmaceuticals, Pfizer, Novartis Pharmaceuticals Corporation, Sanofi, Sunovion Pharmaceuticals, Cipla, Smith & Nephew, Medtronic, SinuSys Corporation, Olympus Corporation and Acclarent among other companies
Browse complete report description and visit our website @ https://www.emergenresearch.com/industry-report/chronic-rhinosinusitis-market
Regional Scope: North America; Europe; Asia Pacific; Central & South America; MEA
Product Outlook (Revenue in Million USD; 2017–2027)
- Steroids
- Topical Nasal Steroid
- Systemic Steroids
- Nasal Irrigation
- Hypertonic and Isotonic Saline
- Steroid Nasal Irrigation
- Topical Antibiotic Therapy
- Surgical Based
- Ethmoidectomy
- Endoscopic Intranasal Intervention
- Others
- Antibiotics
- Amoxicillin-Clavulanate
- Clindamycin
- Sulfamethoxazole
- Levofloxacin
- Macrolide Therapy
- Antifungal Therapy
Disease Outlook (Revenue in Million USD; 2017–2027)
- Anatomical Differences
- Nasal Tumors
- Mucosal Edema
- Non-Allergic Rhinitis
- Immune Deficiency
- Other
Distribution Channel (Revenue in Million USD; 2017–2027)
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Other
North America accounted for the largest market share of approximately, 37.2% in the global Chronic Rhinosinusitis market in 2019 primarily due to growing incidences of chronic asthma and rhinosinusitis symptoms along with competent infrastructure and favorable reimbursement scenarios. Owing to such promising market drivers, the North American market is anticipated to grow significantly through the forecast period.
Thank you for reading our report. For further information or queries about the report or customization options, please get in touch with us. We will ensure your report is tailored according to your requirements.
